The Zhitong Finance App learned that China Merchants Securities International released a research report saying that Jiangxi Biotech (06915.HK) is accelerating the transformation from a single tetanus antitoxin (TAT) leader to a comprehensive antiserum platform. The research pipeline focuses on rigid demand areas where supply is seriously inadequate, and is about to enter the harvest period. For the first time, it will cover a “gain” rating, with a target price of HK$23.6.

The Zhitong Finance App learned that China Merchants Securities International released a research report saying that Jiangxi Biotech (06915.HK) is accelerating the transformation from a single tetanus antitoxin (TAT) leader to a comprehensive antiserum platform. The research pipeline focuses on rigid demand areas where supply is seriously inadequate, and is about to enter the harvest period. For the first time, it will cover a “gain” rating, with a target price of HK$23.6.